ArticleInfection2025
Sero-prevalence of measles and rubella immunoglobulin G serum antibody in individuals 1-30 years old in England in 2018: implications for subsequent outbreaks prediction.
Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMeasles outbreaks have occurred across England since mid-2023. We estimated measles and rubella antibody seroprevalence among individuals in 2018 in English regions outside London, and estimated the effective reproduction number (Re) for measles to predict the potential for outbreaks.
methodsUsing validated enzyme-linked immunosorbent assays, anti-Measles and anti-Rubella IgG antibodies were measured in residual sera from 3758 1-30-year-olds born after introduction of measles-mumps-rubella vaccination who submitted samples to clinical laboratories outside London. The measles Re was calculated using seronegatives defined by the manufacturer's cutoff, mixture modelling, and vaccination coverage data.
resultsUsing the manufacturer's cutoffs, the overall proportion seronegative to measles was 9.2% (95% confidence interval 8.3-10.1), and 10.3% (9.4-11.3) had equivocal results. The respective estimates for rubella were lower at 5.2% (4.6-6.0) and 5.4% (4.7-6.1). For both viruses, equivocal proportions increased with age, consistent with antibody waning. Mixture modelling for measles identified a common seronegative distribution across age groups, with lower proportions seronegative than using the manufacturer's cutoff. Re for measles using the manufacturer's seronegative cutoff (~ 150 mille international units/mL) was 1.00, versus 0.38 and 0.51 using the mixture model and vaccination coverage, respectively.
conclusionsRe for measles estimated from seroepidemiology using an antibody cut-off similar to that considered a correlate of protection for measles was a more accurate predictor of recent measles resurgences outside London than those estimated using mixture modelling of seronegatives or coverage data. Seroepidemiological studies are a useful adjunct to coverage data in monitoring population immunity and in predicting the potential for measles outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.